Tuesday, July 10, 2018
The NIH community and cancer scientists around the world were saddened to learn that Alan Rabson, M.D., a prominent former IRP researcher and Deputy Director of the NIH’s National Cancer Institute (NCI), passed away on July 4 at the age of 92.
Dr. Rabson first joined the NIH in 1955 as a pathologic anatomy resident in the NIH Clinical Center, which had opened just two years before, and he began studying cancer-causing viruses in an NCI intramural laboratory a year later. Over the course of his ensuing six decades with NIH, Dr. Rabson accumulated a great many stories, a few of which we have shared in his own words, pulled from a 1997 “NCI Oral History Project” interview.
Thursday, May 24, 2018
Theodor Kolobow, M.D., passed away on March 24, 2018. He was 87 years old. His contributions while at the NHLBI to the field of cardiovascular and pulmonary research fall nothing short of extraordinary, and include advancements in the development of artificial organs, and the pathophysiology of acute lung injury. Over the course of his career he was actively involved in the innovation and development of new dialysis machines, cuffless endotracheal tubes, and devices to prop open right-sided heart valves, thereby preventing left heart distention during percutaneous cardiopulmonary bypass. He designed special low-resistance endotracheal tubes to limit the necessary ventilatory pressure, in addition to endotracheal tubes that would help to limit bacterial colonization and methods for preventing ventilator associated pneumonias.
Monday, May 21, 2018
James F. Holland, M.D., a renowned cancer expert who was a major figure in the development of cancer chemotherapy, died on March 22, 2018, at the age of 92. Dr. Holland was among the first group of research physicians recruited to the NIH Clinical Center, serving as a senior surgeon at the National Cancer Institute from 1953 to 1954. In that short year at the NIH, he initiated a clinical trial to compare continuous or intermittent treatment with two chemotherapy agents for acute leukemia in children: methotrexate and 6-mercaptopurine. Dr. Holland moved to Roswell Park Memorial Institute in Buffalo before the trial was completed, but he continued to collaborate. His work ultimately turned an incurable illness into one with an 80% survival rate. In 1972, he and his NIH collaborators shared the Albert Lasker Clinical Medical Research Award for "outstanding contribution to the concept and application of combination therapy in the treatment of acute leukemia in children."
Thursday, June 22, 2017
Michael A. Beaven died unexpectedly on Saturday, April 8, 2017, at age 80. Mike was an expert in mast cell biology and beloved friend and colleague of many. He had worked at the NIH since 1962.
In the past seven years during his formal “retirement,” Mike remained incredibly productive, coauthoring more than 20 primary publications as well as a number of reviews; and he continued to perform experimental work as well as being the “go to” scholar in a range of areas.
Friday, May 5, 2017
Claude Klee, a true giant among the many great NIH biochemists, died on Monday, April 3, after suffering a heart attack. She was 85 years old. Claude was a pioneer in the biochemistry of calcium-binding proteins and calcium-dependent signaling. Although retired for more than a decade, she remained an active mentor and advisor at the NIH in the National Cancer Institute (NCI) and a consistent presence on the Bethesda campus until her death.
Tuesday, March 7, 2017
Alexis Shelokov, who studied the polio virus at the NIH in the 1950s and was a powerful scientific force in what would become the famed NIAID Laboratory of Infectious Diseases in Building 7, died on December 12, 2016, in Dallas, Texas. He had a prolific scientific career that took him around the world.